ARTICLE | Finance

Modulating mechanism

Why investors backed neurology company Aptinyx’s $70M series B

December 22, 2017 6:28 PM UTC

Aptinyx Inc. parlayed preclinical proof-of-concept data for NYX-2925 into an untranched $70 million series B round that should give the neurology company runway through YE19, when it expects to have data from Phase II trials from NYX-2925 and a second compound in hand.

Bain Capital Life Sciences led the round. Fellow new investors Adage Capital, Agent Capital, HBM Healthcare Investments, Nan Fung Life Sciences, Partner Fund Management and Rock Springs Capital also participated, along with existing investors New Leaf Venture Partners, Frazier Healthcare Partners, Longitude Capital, Osage University Partners, Adams Street Partners, LVP Life Science Ventures, PathoCapital, Goudy Park Capital, Beecken Petty O’Keefe and Northwestern University...

BCIQ Company Profiles

Aptinyx Inc.

BCIQ Target Profiles

NMDA receptor